What Amgen (AMGN) Said on Its Q3 Earnings Call
Amgen reported Q3 sales growth in rare diseases and oncology, with BLINCYTO up 27% and TEPEZZA down 6%. Positive phase III results were announced for small cell lung cancer, eosinophilic esophagitis, and Sjögren's disease. MariTide obesity drug trials are advancing. Amgen raised 2026 revenue guidance to $38.9B-$39.7B and EPS to $22.90-$23.70, with a 6% dividend increase.
How this was made
The 30-second read
Why it matters
Traders can update valuation models using the raised 2026 revenue and non-GAAP EPS ranges, while pipeline investors may reprice probability-weighted outcomes for IMDELLTRA/IMFINZI, TEZSPIRE, and dazodalibep based on the reported Phase III endpoints and stated regulatory filing plans.
Market read
Raised guidance and multiple positive Phase III readouts provide fresh inputs for both earnings expectations and pipeline valuation, making the update tradable for the next sessions.
What to watch
Inventory build cited for TEPEZZA and rising non-GAAP R&D expense could offset some of the guidance optimism if trends persist into subsequent quarters.
Background
The piece summarizes Amgen’s Q3 earnings call, combining financial performance, raised 2026 guidance, and multiple Phase III clinical readouts across oncology, inflammation, and obesity/sleep apnea programs.
Ticker impact
Amgen raised 2026 revenue guidance to $38.9B-$39.7B and EPS to $22.90-$23.70 after reporting Q3 free cash flow of $3.7B and Phase III readouts.
Likely upward bias as investors price in higher 2026 fundamentals and de-risk pipeline timelines.
The article contains fresh, company-specific guidance numbers and multiple positive Phase III results with stated plans to file with regulators, which are direct drivers for earnings expectations and pipeline valuation.
Market effects
Reinforces investor appetite for large-cap biotech with late-stage oncology and inflammation catalysts, potentially supporting sector multiples.
Primarily US large-cap biotech sentiment; could spill over to healthcare/biopharma peers via read-across on pipeline quality and monitoring-label implications.
Global regulatory filing plans and multinational trial readouts may influence broader biotech risk appetite beyond the US.
Counterpoint
Despite positive Phase III results, adoption and label outcomes (monitoring requirements, outpatient feasibility) may lag, limiting near-term earnings sensitivity.
Key entities
- companyAmgen
Biopharmaceutical company reporting Q3 results, raised 2026 guidance, and positive Phase III data across multiple programs.
- clinical_programIMDELLTRA plus IMFINZI
Phase III DeLLphi-305 combination for first-line maintenance in small cell lung cancer, with median OS 21.1 months vs 12.7 months for IMFINZI alone.
- clinical_programTEZSPIRE
Phase III CROSSING study met co-primary endpoints in eosinophilic esophagitis with sustained benefits through week 52.
- clinical_programdazodalibep
Phase III OASIZ-301 study in systemic Sjögren’s disease met its primary endpoint with placebo-adjusted improvements.
- clinical_programMariTide
Obesity candidate with completed enrollment in Phase III sleep apnea studies and a cardiovascular outcomes study, plus initiation of Phase III type 2 diabetes studies.
